Dukem Bio Invests KRW 34.3 Billion in Jeongeup to Build Korea's First Radiopharmaceutical CDMO Plant
Construction to Begin in June Next Year, Commercial Operation Targeted for Second Half of 2029
Integrating Isotope Production and Export in One Facility
Dukem Bio, the radiopharmaceutical subsidiary of GeoYoung Group, will establish the nation's first CDMO (Contract Development and Manufacturing Organization) plant specialized in radiopharmaceutical therapies (RPT) for a domestic company in Jeongeup, Jeonbuk.
After the signing ceremony of the Dukem Bio investment agreement held on the 4th at the meeting room of the Jeonbuk Special Self-Governing Province Office in Jeonju, the attendees are taking a commemorative photo. From the left: Won-Tak Lee, Governor of Jeonbuk Special Self-Governing Province; Sangwoo Kim, CEO of Dukem Bio; Junbyung Yoon, Member of the National Assembly; Jongwoo Kim, Vice Chairman of Dukem Bio; Jinhyuk Yoo, Head of Jeonbuk Research and Development Special Zone Headquarters; Haksoo Lee, Mayor of Jeongeup. Dukem Bio
View original imageDukem Bio announced on the 7th that it had signed an investment agreement worth KRW 34.3 billion on the 4th with Jeonbuk Special Self-Governing Province and Jeongeup City to construct an 'RPT specialized CDMO plant and R&D center.'
This project, to be built in phases by 2032 in the High-Tech Industrial Zone in Sinjeong-dong, Jeongeup, will begin with Phase 1, starting construction in June next year and investing approximately KRW 13.6 billion through May 2030 to establish a manufacturing center for diagnostics and therapeutics, an R&D center, and the first manufacturing facility. In Phase 2, which spans 2031–2032, the company will invest an additional KRW 20.7 billion to build a radiopharmaceutical isotope manufacturing center, an active pharmaceutical ingredient (API) manufacturing center, and a second manufacturing facility.
The investment will be raised through about KRW 19.3 billion of equity capital and KRW 15 billion in facilities financing loans, with no plans for a paid-in capital increase. Out of the total investment, KRW 22.8 billion will be allocated to machinery and equipment and KRW 10.3 billion to construction.
The Jeongeup High-Tech Industrial Zone, where the new plant will be located, has been designated as a “Special Opportunity Development Zone,” so the company expects tax benefits as well. The new facility will be eligible for a 100% exemption from income and corporate taxes for the first five years and a 50% reduction for the following two years; acquisition and property taxes for land and buildings will be fully waived, while property tax will also be exempted for the first five years.
The new plant will be equipped with a cyclotron for the production of radioisotopes and the first manufacturing facility with GMP (Good Manufacturing Practice) standards. With a planned annual production capacity of approximately 1,000 batches, it will have the largest capacity among all Dukem Bio facilities. After passing the Korea Ministry of Food and Drug Safety’s GMP compliance assessment and obtaining production approval from the Nuclear Safety and Security Commission, the company aims to begin commercial production in the second half of 2029.
The R&D center built on the same site will conduct research on isotope production technology, pharmaceutical chemistry, manufacturing and quality control (CMC), and nuclear medicine imaging using artificial intelligence (AI). The company also plans to add production facilities for therapeutic alpha- and beta-emitting radionuclides, as well as an API manufacturing center in the future.
Sangwoo Kim, CEO of Dukem Bio, said, "Competitiveness in the radiopharmaceutical business is determined by the supply chain, which spans from sourcing isotopes to GMP production, quality control, and delivery," adding, "Our goal is to design and establish all aspects of this supply chain, from radioisotope production to CDMO and API exports, in one location."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Dukem Bio has already secured CDMO track records for two Alzheimer’s tau PET diagnostic substances, partnering with Lantheus (USA) and Life Molecular Imaging (Germany). Once the Jeongeup plant is operational, same-day supply will be possible not only for the Honam region but also for the Chungcheong region and parts of Gyeongsang, contributing to strengthened regional supply chain stability for radiopharmaceuticals.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.